Patients and their families are starting to inquire about the new Alzheimer's drug approved this week by the US Food and Drug Administration. Shipments of the medication are expected to go out in just ...

The US Food and Drug Administration on Monday approved the use of the experimental drug aducanumab for early phases of Alzheimer's disease -- despite an FDA advisory committee concluding last year ...

Aducanumab is a human recombinant monoclonal antibody (mAb) derived from a de-identified library of B cells collected from healthy elderly subjects with no signs of cognitive impairment and ...

Aduhelm (aducanumab-avwa) is a prescription drug that’s used to treat Alzheimer’s disease. The drug comes as a liquid solution for intravenous (IV) infusion by a healthcare professional. It’s usually ...

TORONTO and CAMBRIDGE, Mass., Dec. 05, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody ...

The high-profile failure of Biogen’s Alzheimer’s disease drug aducanumab (Aduhelm), punctuated by the company’s decision in January 2024 to discontinue sales, highlights the common struggles faced by ...

Yesterday, the Food and Drug Administration (FDA) approved aducanumab as a treatment for Alzheimer's. This was history-making, as it was the first medication approved to treat Alzheimer's since 2003.

James Robinson is a professor of health economics at the University of California, Berkeley, School of Public Health. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the ...

The BMJ is an international peer reviewed medical journal and a fully "online first" publication. Our publishing model–"continuous publication"– means that all articles appear on bmj.com before being ...

At its November meeting, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) voted against Biogen's controversial Alzheimer's drug aducanumab (Aduhelm), ...